Mesenchymal Stem Cells (MSCs) and Facet Arthritis

Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be found in many tissues throughout the body, including the bone marrow, adipose tissue, and even umbilical cord blood. MSCs have the ability to differentiate into a number of different cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. This ability to differentiate into multiple cell types makes MSCs a promising tool for the treatment of a variety of diseases, including facet arthritis. Facet arthritis is a type of degenerative arthritis that affects the facet joints, which are the small joints located between the vertebrae in the spine. Facet arthritis is typically caused by the wear and tear of the cartilage that covers the facet joints. This wear and tear can be the result of aging, injury, or repetitive motion. Facet arthritis can lead to the formation of bone spurs, which can cause the joints to become inflamed and painful. MSCs have the ability to differentiate into chondrocytes, which are the cells that make up cartilage. This ability to differentiate into chondrocytes makes MSCs a potential treatment for facet arthritis. In a study conducted on rats, it was shown that the injection of MSCs into the facet joints of rats with facet arthritis resulted in the regeneration of cartilage and the prevention of further degeneration of the facet joints. The use of MSCs for the treatment of facet arthritis is still in the early stages of research. More research is needed to determine the safety and efficacy of MSCs for the treatment of facet arthritis. However, the results of the studies conducted thus far are promising and suggest that MSCs may be a safe and effective treatment for facet arthritis.

 "New Approaches to Treat Osteoarthritis with Mesenchymal Stem Cells." Accessed 24 Oct. 2022.

 "First Human Report of Relief of Lumbar and Cervical Discogenic ...." 28 Jun. 2022, Accessed 24 Oct. 2022.

 "Allogeneic BM-MSCs in Patients With Lumbar Facet Arthropathy." 1 Jun. 2020, Accessed 24 Oct. 2022.

The information below is the recommended stem cell therapy protocol for this condition 

Route of AdministrationDoseTime (Days)Total Cells
Myers cocktail/NAD50,000,0002N/A
Exosome IV10,000,00060N/A
Intrathecal (site of injury)50,000,000150,000,000
Spinal Level/Facet50,000,000150,000,000